1 study on Nfkappab inhibition mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**alpha-MSH and KPV represent a dual-action immunotherapeutic strategy**: simultaneously suppressing pro-inflammatory cytokine cascades and actively inducing antigen-specific tolerance via CTLA4(+)/IL-10(+) T cells — …